Back to dashboard
CommercialCoverageMedium impact

08.01.64e, Avelumab (Bavencio®)

Independence Blue Cross·Oncology·Pharmacy
Effective date
Dec 29, 2025
We identified it
Jun 19, 2026
Days to comply
—

Summary

Updated medical necessity criteria and medical coding guidelines for Avelumab (Bavencio®), a cancer immunotherapy drug. This affects pharmacy benefit coverage and billing requirements for this specific oncology medication.

Action Required

Action needed
By December 29, 2025: Billing team must review updated medical necessity criteria for Avelumab (Bavencio®) claims and verify compliance with new coding guidelines. Update prior authorization documentation requirements in billing system. Notify oncology providers of revised coverage criteria to ensure proper documentation before prescribing.

Related policy hubs